⚠ Coverage and Cost Gate the DemandModerate threat

The demand for incretin drugs is vast, but converting that demand into revenue depends on who pays, and coverage remains a real and contested gate. The drugs are expensive, and much of the potential market — especially for obesity, which insurers and governments have historically been reluctant to treat as a medical condition — hinges on securing broad reimbursement. Where coverage is denied or restricted, the enormous latent demand cannot fully translate into sales.

The danger is that payers, facing budgets strained by drugs this popular and this costly, push back hard. Insurers restrict eligibility, governments negotiate prices, employers balk at the expense of covering a large share of their workforce, and the sheer scale of potential spending — treating a substantial fraction of the population — creates pressure to limit access precisely because the demand is so large. A market limited by willingness to pay has its realized size set by others.

Lilly's position is strong: the drugs' expanding benefits for heart, kidney, and other conditions strengthen the case for coverage, cheaper oral versions could widen access, and the value of treating obesity's downstream costs is increasingly recognized. But an owner should recognize that the incretin opportunity, however vast in principle, is gated by coverage and price decisions Lilly does not fully control, that payers have strong incentives to restrain spending on a drug this widely wanted, and that the gap between potential and realized demand turns on a reimbursement fight far from settled — realized prices fell 13% in the second quarter of 2026, and 36% outside the United States.¹